A high-CBD cannabis extract (CBD-X) reduced inflammatory cytokines from human immune cells and significantly lessened arthritis severity in two different mouse models of rheumatoid arthritis.
Read this if you have rheumatoid arthritis and follow cannabinoid research — this is the strongest preclinical evidence yet, though human trials are still needed.
What the researchers found
This study takes the rheumatoid arthritis (RA) cannabis research a significant step forward from RTHC-00097 (CBG in RA cells) by testing a high-CBD extract not just in isolated human cells but also in two animal models of the disease.
The ex vivo experiments showed that CBD-X inhibited the secretion of key inflammatory cytokines: IL-1β from macrophages and IL-8, IL-6, and TNF-α from human neutrophils — all central players in RA joint destruction. The extract also attenuated NF-κB p65 and Akt phosphorylation, two signaling pathways that drive the inflammatory cascade.
Then the researchers took it to live animals using two established mouse models of RA. In collagen-induced arthritis (CIA) — a model that mimics the autoimmune component of RA — and collagen antibody-induced arthritis (CAIA) — a model driven by antibody-mediated inflammation — CBD-X treatment reduced disease severity.
The two-model approach is important because RA involves both autoimmune and inflammatory components. Showing efficacy in both CIA (autoimmune-driven) and CAIA (antibody-driven) suggests CBD-X may work across different aspects of RA pathophysiology rather than targeting just one pathway.
The combination of human cell data and animal efficacy data makes this one of the more complete preclinical packages in the cannabinoid-arthritis space. It bridges the gap between 'CBD reduces inflammation in a dish' and 'CBD reduces disease in an animal' — the next step would be human trials.
Why it matters
RA affects approximately 1% of the global population and current treatments — while effective for many — include medications with serious side effects (immunosuppression, infection risk, liver damage). If a CBD-based treatment could provide meaningful relief with a better safety profile, it would be significant for the millions who don't respond well to or can't tolerate current RA drugs. This study provides the strongest preclinical evidence yet for that possibility.
The numbers in context
CBD-X inhibited IL-1β from macrophages and IL-8, IL-6, TNF-α from human neutrophils. Attenuated NF-κB p65 and Akt phosphorylation in neutrophils. Reduced disease severity in both CIA and CAIA mouse models. RA affects approximately 1% of the global population.
How the study worked
Combined ex vivo and in vivo study. Ex vivo: tested CBD-X on macrophages and primary human neutrophils, measuring cytokine secretion (IL-1β, IL-8, IL-6, TNF-α) and signaling pathways (NF-κB p65, Akt phosphorylation). In vivo: two murine RA models — collagen-induced arthritis (CIA, autoimmune model) and collagen antibody-induced arthritis (CAIA, antibody-mediated model) — treated with CBD-X and assessed for disease severity.
Who was studied
Two murine models of rheumatoid arthritis and human immune cells were used.
What this study cannot tell us
Mouse models of RA don't perfectly replicate human disease — many drugs that work in CIA and CAIA mice fail in human RA trials. The CBD-X extract is a whole-plant extract, not pure CBD, so specific active components aren't fully defined. Dosing in mice doesn't directly translate to human dosing. The ex vivo human cell work used isolated cell types rather than the complex joint environment. No long-term safety or efficacy data. The specific formulation tested (CBD-X) may not represent commercially available CBD products.
How to read the evidence
Combined ex vivo (human cells) and in vivo (two mouse models) study. One of the more complete preclinical packages in cannabinoid-arthritis research. However, many promising mouse RA treatments have failed in human trials — animal efficacy doesn't guarantee clinical efficacy.
When this study was published
Published in 2025. Human clinical trials of CBD for rheumatoid arthritis may be in development.
The bigger picture
This advances beyond RTHC-00097 (CBG in RA cells, which was purely in vitro) by adding animal model data. Together with RTHC-00098 (CBD and innate immunity) and RTHC-00109 (cannabinoids for psoriasis), a pattern is emerging: CBD-based preparations show anti-inflammatory effects across multiple autoimmune and inflammatory conditions in preclinical models. The consistent gap across all of these is the lack of human clinical trial data.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Would CBD-X be effective in a human RA clinical trial? Can the specific components of CBD-X that drive the anti-inflammatory effect be identified? Would CBD-X work as an add-on to current RA medications, or would interactions (via CYP450 inhibition, see RTHC-00091) be a concern? What's the optimal dosing regimen for sustained anti-inflammatory effect in RA?
Read the original research
High CBD extract (CBD-X) modulates inflammation and immune cell activity in rheumatoid arthritis.
Frontiers in immunology, 16, 1599109
Frontiers in Immunology is a reputable journal focusing on immunological research.
Citation
Aswad, Miran; Pechkovsky, Antonina; Ghanayiem, Narmeen; Hamza, Haya; Louria-Hayon, Igal. (2025). High CBD extract (CBD-X) modulates inflammation and immune cell activity in rheumatoid arthritis.. Frontiers in immunology, 16, 1599109. https://doi.org/10.3389/fimmu.2025.1599109
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk
- THC and Ibuprofen: Safe to Combine? What the Research Says